ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-OR029

Genetic Architecture of Renal Cell Cancer (RCC) in the Million Veteran Program Highlights Differences by Ancestry and Papillary Subtype

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Complex Kidney Traits

Authors

  • Mamak, Fatih, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Wang, Guanchao, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Chen, Hua-Chang, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Triozzi, Jefferson Lorenzo, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Tao, Ran, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Hung, Adriana, VA Tennessee Valley Healthcare System, Nashville, Tennessee, United States

Group or Team Name

  • KidPhenGen Vanderbilt Precision Nephrology Program.
Background

Kidney cancer is among the top 10 cancers in the US, affecting more than 600,000 people. RCC is more common in African Americans and men. People with advanced kidney disease have a 5-fold increased risk of RCC.

Methods

GWASs of RCC and of papillary renal cell carcinoma (PRCC), stratified by genetic ancestry were completed. Controls included European ancestry (EUR) 448,131; African ancestry (AFR) 120,446 and Admixed American (AMR) 59,942 individuals.; RCC cases included EUR 4115, AFR 1422, and AMR 596 cases. GWASs were adjusted for age, sex and 10 principal components of ancestry.

Results

The mean age was 61 years (SD 15) for cases and 65 years (SD 10) controls. Ancestry was: 69% EUR, 18% AFR and 9% AMR. There were 10 independent loci associated with RCC overall for EUR. The strongest association was with MYEOV (rs7939454; p-value 9.92E-14), followed by SSPN/ITPR2 (rs4963975; p: 8.74E-10) and MAD1L1 (rs1801368; p: 2.01E-09). There were 9 independent loci associated with PRCC in EUR. The strongest association was with MYEOV (rs10908258;p:1.17E-11), five loci were in CKD genes (IL6R, IGFBP3, SHROOM3, TRPC7, SLC5AA48). VHL was associated with RCC (rs3087462; p:1.85E-16) and PRCC (rs7629500; p: 8.98E-08) only in AFR . Most loci in cancer genes were known. Novel loci in 5 genes are reported-not replicated yet: ANKL2, IRAK2, GYPB, PTPN13, SNX16 (Table 1).

Conclusion

Our study supports important differences in the genetic architecture of RCC by ancestry, including in the contributions of VHL to the risk of RCC and PRCC, only observed for AFR in this study. Longitudinal studies evaluating the value of these markers in prognosis and recurrence risk are needed. Also for the association CKD and PRCC.

Table 1. Genetic variants associated with RCC and PRCC in EUR & AFR

Funding

  • Veterans Affairs Support

Digital Object Identifier (DOI)